PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study

Summary.  Background and objectives: Genes encoding protein C anticoagulant pathways are candidates for atherothrombotic and other aging‐related disorders. Methods: Using a tagSNP approach, and data from the Cardiovascular Health Study (CHS), we assessed associations of common polymorphisms of PROC, PROS1 and PROCR with: (i) plasma protein C, soluble protein C endothelial receptor (sEPCR) and protein S levels measured in a subsample of 336 participants at study entry; and (ii) risk of incident clinical outcomes [coronary heart disease (CHD), stroke, and mortality] in 4547 participants during follow‐up. Secondarily, we explored associations between plasma protein C, protein S and sEPCR levels and other candidate genes involved in thrombosis, inflammation, and aging. Results: The PROCR Ser219Gly polymorphism (rs867186) was strongly associated with higher sEPCR levels, explaining 75% of the phenotypic variation. The PROCR Ser219Gly variant was also associated with higher levels of circulating protein C antigen. An IL10 polymorphism was associated with higher free protein S levels. The minor alleles of PROC rs2069901 and PROS1 rs4857343 were weakly associated with lower protein C and free protein S levels, respectively. There was no association between PROCR Ser219Gly and risk of CHD, stroke, or mortality. The minor allele of another common PROCR tagSNP, rs2069948, was associated with lymphoid PROCR mRNA expression and with increased risk of incident stroke and all‐cause mortality, and decreased healthy survival during follow‐up. Conclusions: A common PROCR variant may be associated with decreased healthy survival in older adults. Additional studies are warranted to establish the role of PROCR variants in ischemic and aging‐related disorders.

[1]  C. Carty,et al.  Common genetic variants associated with plasma fibrin D‐dimer concentration in older European‐ and African‐American adults , 2008, Journal of thrombosis and haemostasis : JTH.

[2]  M. Boehnke,et al.  So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. , 2007, American journal of human genetics.

[3]  Nigel Mackman,et al.  Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C , 2007, The Journal of experimental medicine.

[4]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[5]  C. Esmon,et al.  Non‐hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  J. Griffin,et al.  The cytoprotective protein C pathway. , 2007, Blood.

[7]  P. Winship,et al.  Regulation of the human protein S gene promoter by liver enriched transcription factors , 2006, British journal of haematology.

[8]  J. Landry,et al.  Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene. , 2006, Blood.

[9]  R. Bertina,et al.  The Constitutive Expression of Anticoagulant Protein S Is Regulated through Multiple Binding Sites for Sp1 and Sp3 Transcription Factors in the Protein S Gene Promoter* , 2006, Journal of Biological Chemistry.

[10]  J. Patsch,et al.  Endothelial Protein C Receptor-Dependent Inhibition of Migration of Human Lymphocytes by Protein C Involves Epidermal Growth Factor Receptor1 , 2006, The Journal of Immunology.

[11]  C. Esmon,et al.  The Ser219–>Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  J S Yudkin,et al.  EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. , 2005, Atherosclerosis.

[13]  S. Hunt,et al.  Genome-Wide Associations of Gene Expression Variation in Humans , 2005, PLoS genetics.

[14]  B. Dahlbäck,et al.  The anticoagulant protein C pathway , 2005, FEBS letters.

[15]  F R Rosendaal,et al.  Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis , 2004, Journal of thrombosis and haemostasis : JTH.

[16]  L. Almasy,et al.  Protein C Levels Are Regulated by a Quantitative Trait Locus on Chromosome 16: Results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  D. Lin,et al.  Haplotype‐based association analysis in cohort studies of unrelated individuals , 2004, Genetic epidemiology.

[18]  Justo Aznar,et al.  Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk , 2004, Thrombosis and Haemostasis.

[19]  J. Reny,et al.  A HAPLOTYPE OF THE EPCR GENE IS ASSOCIATED WITH INCREASED PLASMA LEVELS OF sEPCR AND IS A CANDIDATE RISK FACTOR FOR THROMBOSIS Short title : EPCR gene , sEPCR level and thrombotic , 2003 .

[20]  F. Rosendaal,et al.  Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C‐deficient family , 2004, Journal of thrombosis and haemostasis : JTH.

[21]  K. Fukudome,et al.  Expression and function of the endothelial protein C receptor in human neutrophils. , 2003, Blood.

[22]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  José A Fernández,et al.  Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.

[24]  L. Almasy,et al.  A Quantitative Trait Locus Influencing Free Plasma Protein S Levels on Human Chromosome 1q: Results From the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project , 2003, Arteriosclerosis, Thrombosis and Vascular Biology.

[25]  A. D’Angelo,et al.  Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. , 2002, Blood.

[26]  L. Almasy,et al.  Genetic determinants of hemostasis phenotypes in Spanish families. , 2000, Circulation.

[27]  L. Guize,et al.  Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. , 1999, Arteriosclerosis, Thrombosis and Vascular Biology.

[28]  M. Cushman,et al.  Correlates of Antithrombin, Protein C, Protein S, and TFPI in a Healthy Elderly Cohort , 1998, Thrombosis and Haemostasis.

[29]  J. Williamson,et al.  Predicting future years of healthy life for older adults. , 1998, Journal of clinical epidemiology.

[30]  C. Esmon,et al.  Identification of functional endothelial protein C receptor in human plasma. , 1997, The Journal of clinical investigation.

[31]  M. Aiach,et al.  The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. , 1995, Blood.

[32]  D. Cooper,et al.  Polymorphic variation in the human protein C (PROC) gene promoter can influence transcriptional efficiency in vitro , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  P. Reitsma,et al.  Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[34]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[35]  I. Peake.  International Society on Thrombosis and Haemostasis , 1974, Thrombosis and Haemostasis.

[36]  C. Carlson,et al.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.